Association of Cancer with Heart Failure and the Prognostic Value of NT-proBNP in Cancer Patients: Findings from the NHANES (1999-2018)

Evidence regarding the association between cancer and heart failure (HF) is scarce. This study is to investigate the association between HF and cancer and explore the prognostic value of NT-proBNP in cancer patients. This cohort study used National Health and Nutrition Examination Survey data from 1...

Full description

Saved in:
Bibliographic Details
Published in:Current oncology (Toronto) 2024-09, Vol.31 (9), p.4927-4939
Main Authors: Zeng, Qingping, Chang, Weihong, Zhang, Rui, Fan, Hongxuan, Dou, Zixuan, Liu, Aman, Yu, Jie, Zhou, Boda
Format: Article
Language:English
Subjects:
Adult
Aged
Cancer
Cancer patients
Care and treatment
Cohort Studies
Female
Heart failure
Heart Failure - blood
Heart Failure - complications
Humans
Male
Middle Aged
Natriuretic Peptide, Brain - blood
Neoplasms - blood
Neoplasms - complications
NT-proBNP
Nutrition Surveys
Oncology, Experimental
Peptide Fragments - blood
Prognosis
survival
Valsartan
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Evidence regarding the association between cancer and heart failure (HF) is scarce. This study is to investigate the association between HF and cancer and explore the prognostic value of NT-proBNP in cancer patients. This cohort study used National Health and Nutrition Examination Survey data from 1999 to 2018 and linked mortality information until 2019. We included all participants with valid answer to questions regarding self-reported cancer and HF. Multivariable logistic regression was used to estimate odds ratios (ORs) and 95% CIs. Our study included data from 54,847 adult participants. During a median (IQR) follow-up of 9.6 (4.0-15.1) years, 7674 deaths were recorded. HF was associated with an increased occurrence of cancer after propensity score matching (OR = 1.46, 95% CI: 1.17-1.82, < 0.001). Cancer was associated with a higher occurrence of HF (OR = 1.33, 95% CI: 1.11-1.59, = 0.002). Kaplan-Meier survival analysis over 10 years revealed the shortest survival in patients with both HF and cancer (log-rank < 0.0001). Importantly, NT-proBNP was significantly higher in cancer patients, no matter whether with known HF ( < 0.01). In cancer patients without HF, NT-proBNP higher than 51.51 pg/mL was associated with shorter survival (log-rank < 0.0001). Findings from this cohort study suggest that HF is significantly associated with cancer. NT-proBNP was higher in cancer patients, with significant prognostic value in cancer patients.
ISSN:1198-0052
1718-7729
1718-7729
DOI:10.3390/curroncol31090365